CPAP Therapy Improves Cognition in Parkinson's Patients with Sleep Apnea
First 6-month RCT shows PAP therapy meaningfully improves MoCA scores and motor function in Parkinson's patients with OSA.
Summary
A randomized controlled trial of 94 Parkinson's disease patients with obstructive sleep apnea found that 6 months of positive airway pressure (PAP/CPAP) therapy improved global cognition compared to placebo nasal dilator strips. The adjusted intention-to-treat analysis showed a 1.44-point MoCA improvement in the PAP group versus controls. Per-protocol analyses confirmed a 1.43-point benefit among adherent users. Secondary gains included better depression scores, sleep quality, and performance on executive and psychomotor tasks. Motor function also improved significantly in per-protocol analyses. This is the largest and longest RCT of OSA treatment in any neurodegenerative disease, suggesting that screening Parkinson's patients for sleep apnea and treating it could slow cognitive decline.
Detailed Summary
Parkinson's disease (PD) is the fastest-growing neurodegenerative disorder globally, and cognitive impairment affects 20–40% of patients even in early stages, ultimately progressing to dementia in up to 80%. Obstructive sleep apnea (OSA) — characterized by intermittent hypoxemia and sleep fragmentation — affects 20–60% of PD patients and has been linked to worsened nonmotor symptoms including cognition. Despite observational evidence suggesting PAP therapy could help, no adequately powered, long-duration RCT had tested this hypothesis in PD until now.
The COPE-PAP trial enrolled 94 participants (mean age 67.3 years, 31% female) with confirmed PD, mild cognitive impairment (MoCA ≤ 27, mean 22.7), and moderate-to-severe OSA (RDI ≥ 15/hour). Participants were randomized 1:1 to auto-PAP therapy or nasal dilator strips (placebo) for 6 months at McGill University Health Centre. Outcome assessors were blinded; participants were told both interventions treated OSA. The primary endpoint was change in MoCA score from baseline to 6 months, analyzed by intention-to-treat (ITT).
In the unadjusted ITT analysis, the PAP group improved by 0.60 MoCA points (95% CI: −0.08 to 1.29) while the control group declined by 0.39 points (95% CI: −1.21 to 0.43), yielding a between-group difference of 1.00 point (95% CI: −0.06 to 2.05) — trending toward significance. Crucially, adjusted ITT analyses controlling for age, sex, BMI, depression, psychoactive medication changes, and hypertension showed a statistically significant improvement of 1.44 MoCA points (95% CI: 0.09 to 2.79) in the PAP group. Per-protocol analyses among the 33 adherent PAP users versus 41 controls confirmed this benefit at 1.43 points (95% CI: 0.054 to 2.81).
Beyond cognition, PAP therapy produced meaningful secondary benefits. Depression scores (BDI-II), sleep quality (PD Sleep Scale), and nonmotor symptom burden (MDS-UPDRS Part 1) all improved significantly in the PAP group. Exploratory neurocognitive testing revealed specific gains in executive function and psychomotor speed tasks. Notably, per-protocol analyses showed statistically significant improvement in motor function (MDS-UPDRS motor subscale) in PAP-treated versus control participants — a finding with major implications given the limited disease-modifying options for PD motor symptoms.
This trial is the largest and longest RCT of OSA treatment in any neurodegenerative condition. Its 6-month duration contrasts with a prior 3–6 week PD RCT that showed no cognitive benefit, suggesting treatment duration is critical. Caveats include the inability to fully blind participants, moderate PAP adherence (33 of 48 randomized remained adherent at 6 months), and the single-center design. Nonetheless, the convergent ITT and per-protocol findings, alongside improvements across multiple secondary outcomes, build a compelling case that OSA is a modifiable contributor to cognitive and motor decline in PD — and that treating it should become standard clinical practice.
Key Findings
- Adjusted ITT analysis: PAP therapy improved MoCA by 1.44 points vs. controls (95% CI: 0.09–2.79), a statistically significant difference
- Per-protocol analysis (adherent users): adjusted between-group MoCA difference of 1.43 points (95% CI: 0.054–2.81) favoring PAP
- Unadjusted ITT: PAP group gained 0.60 MoCA points while control group declined 0.39 points over 6 months (between-group difference 1.00, 95% CI: −0.06 to 2.05)
- Motor function (MDS-UPDRS motor subscale) improved significantly in per-protocol PAP users vs. controls
- Depression scores (BDI-II) and sleep quality (PD Sleep Scale) improved significantly with PAP therapy
- Nonmotor symptom burden (MDS-UPDRS Part 1) improved in the PAP group
- Executive function and psychomotor speed tasks showed significant improvement in exploratory neurocognitive testing in the PAP group
Methodology
Single-blind, parallel-group RCT (COPE-PAP, NCT02209363) at McGill University Health Centre; 94 PD patients with MoCA ≤ 27 and OSA (RDI ≥ 15/hour) randomized 1:1 to auto-PAP or nasal dilator strips (placebo) for 6 months. Primary outcome (MoCA change) analyzed by ITT with last observation carried forward; sensitivity analyses adjusted for age, sex, BMI, depression, psychoactive medication changes, and hypertension via linear regression. Per-protocol analyses included 33 adherent PAP users and 41 controls who completed 6-month assessment.
Study Limitations
Participants could not be fully blinded to treatment assignment, introducing potential performance bias, though outcome assessors were blinded. PAP adherence was moderate — only 33 of 48 randomized participants remained on therapy at 6 months, limiting ITT power. The trial was conducted at a single center in Canada, which may limit generalizability; funding from Philips and Vitalaire (PAP device/supply companies) represents a potential conflict of interest, though funders had no role in data analysis or reporting.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.